HVIVO PLC

Board/Management Information • Sep 1, 2025

National Storage Mechanism | Additional information

RNS Number : 3425X

hVIVO PLC

01 September 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

Appointment of Non-Executive Chair

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials , confirms that, further to its announcement on 29 July 2025, Shaun Chilton has today joined the Board of Directors as Non-Executive Chair with immediate effect.

Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group.

Elaine Sullivan, Interim Chair & Senior Non-Executive Director of hVIVO plc, said: "We are delighted to welcome Shaun to the Board of hVIVO. Shaun brings a wealth of sector-relevant experience and we believe his expertise will support us as we continue to grow and diversify the Group. As a Board we look forward to working closely with Shaun to help deliver on the Company's mission and execute on our strategy."

Shaun Chilton, incoming Non-Executive Chair of hVIVO plc, said: "I am pleased to join the Board of hVIVO plc, a Company which I believe has excellent prospects as it continues to diversify its service offering while leading the global charge in delivering exceptional human challenge trial services to its clients."

Additional Information on the Board Appointment

The following additional information is provided with regards to the appointment of Shaun Edward Chilton ,  aged 57 , in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

Current directorships/partnerships:	Former directorships/partnerships (within the last five years):
Avacta Group plc	C7 Health Limited
Bellbrook Consulting Limited	Clinigen Clinical Trials Limited
Mustang Bidco Limited	Clinigen Consulting Limited
Mustang Midco Limited	Clinigen CTS Limited
Mustang Topco Limited	Clinigen Gap Limited
	Clinigen Healthcare Limited
	Clinigen Holdings Limited
	Clinigen International Holdings Limited
	Clinigen Limited
	Clinigen Pharma Limited
	Definigen Limited
	IDIS GA Limited
	IDIS Group Holdings Limited
	IDIS Group Limited IDIS Limited
	IDIS MA Limited
	IDIS Pharma Limited
	Iovance Biotherapeutics UK SP Ltd
	Keats Healthcare Limited

Shaun does not hold any shares or options in the Company.

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

For further information please contact:

hVIVO plc		+44 (0)20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				+44 (0)20 7220 0500
Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)			+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)			+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings  Lianne Applegarth		+44 (0)20 7933 8780 or  [email protected] +44 (0)7980 541 893 / +44 (0)7407 804 654 +44 (0)7584 391 303

Notes to Editors

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS , hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences , offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp . Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOASDLFWFEISESA